Our Portfolio
Our broad portfolio of cancer-focused projects spans therapeutics, vaccines, diagnostics, medical devices, software and AI.
As the second biggest oncology out-licensor globally, and with exclusive rights to over £400 million of world-class cancer research each year, we're a powerful partner in the fight to conquer cancer.
Our pipeline
We have a pipeline of breakthrough medicines for cancer patients, with agents across the full spectrum of the drug discovery process, from early stage discovery through to first-in-human studies and beyond.
Our licensing opportunities
We hold the rights to a wide variety of oncology-focused projects available for licensing or collaboration.
Our startups
Through our collaborative approach, we've supported the formation and development of more than 60 startups across a wide range of therapeutics, diagnostics and medtech.